Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/119455
Campo DC Valoridioma
dc.contributor.authorMartín Llahí, Martaen_US
dc.contributor.authorNoëlle Pépin, Marieen_US
dc.contributor.authorGuevara, Mónicaen_US
dc.contributor.authorDíaz, Fernandoen_US
dc.contributor.authorTorre, Aldoen_US
dc.contributor.authorMonescillo Francia, Alberto Fernandoen_US
dc.contributor.authorRodés, Juanen_US
dc.contributor.authorGinés, Pereen_US
dc.date.accessioned2022-11-28T18:22:51Z-
dc.date.available2022-11-28T18:22:51Z-
dc.date.issued2008en_US
dc.identifier.issn0016-5085en_US
dc.identifier.urihttp://hdl.handle.net/10553/119455-
dc.description.abstractBackground & Aims: Hepatorenal syndrome is common in patients with advanced cirrhosis and constitutes a major problem in liver transplantation. There is no effective medical treatment for hepatorenal syndrome. Methods: Forty-six patients with cirrhosis and hepatorenal syndrome, hospitalized in a tertiary care center, were randomly assigned to receive either terlipressin (1–2 mg/4 hour, intravenously), a vasopressin analogue, and albumin (1 g/kg followed by 20–40 g/day) (n = 23) or albumin alone (n = 23) for a maximum of 15 days. Primary outcomes were improvement of renal function and survival at 3 months. Results: Improvement of renal function occurred in 10 patients (43.5%) treated with terlipressin and albumin compared with 2 patients (8.7%) treated with albumin alone (P = .017). Independent predictive factors of improvement of renal function were baseline urine volume, serum creatinine and leukocyte count, and treatment with terlipressin and albumin. Survival at 3 months was not significantly different between the 2 groups (terlipressin and albumin: 27% vs albumin 19%, P = .7). Independent predictive factors of 3-month survival were baseline model for end-stage liver disease score and improvement of renal function. Cardiovascular complications occurred in 4 patients treated with albumin alone and in 10 patients treated with terlipressin and albumin, yet permanent terlipressin withdrawal was required in only 3 cases. Conclusions: As compared with albumin, treatment with terlipressin and albumin is effective in improving renal function in patients with cirrhosis and hepatorenal syndrome. Further studies with large sample sizes should be performed to test whether the improvement of renal function translates into a survival benefit.en_US
dc.languageengen_US
dc.relation.ispartofGastroenterologyen_US
dc.sourceGastroenterology [0016-5085], v. 134(5), pp. 1352-1359 (Mayo 2008)en_US
dc.subject32 Ciencias médicasen_US
dc.subject320503 Gastroenterologíaen_US
dc.subject.otherTerlipressimen_US
dc.subject.otherAlbuminen_US
dc.subject.otherCirrhosisen_US
dc.subject.otherHepatorenal syndromeen_US
dc.titleTerlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized studyen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1053/j.gastro.2008.02.024en_US
dc.description.lastpage1359en_US
dc.identifier.issue5-
dc.description.firstpage1352en_US
dc.relation.volume134en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.numberofpages8en_US
dc.utils.revisionen_US
dc.date.coverdateMayo 2008en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.scieSCIE
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-9490-4427-
crisitem.author.fullNameMonescillo Francia, Alberto Fernando-
Colección:Artículos
Vista resumida

Citas de WEB OF SCIENCETM
Citations

403
actualizado el 08-dic-2024

Visitas

64
actualizado el 16-nov-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.